---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-003814"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T11:37:21.448772+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax names Metzger CEO as Morrison moves to President, Head of R&D

## Summary
- Michael Metzger appointed CEO, effective immediately; previously President & COO.
- Briggs Morrison becomes President, Head of R&D; remains on board.
- Metzger base salary $640,000, target bonus 60% of base; Morrison base $637,500, bonus up to 50%.
- Transition aligns roles with expertise; Metzger to focus on strategic vision and commercial prep.
- Morrison to focus on advancing SNDX-5613 and axatilimab toward NDA filings in 2023.

## SEC filing metadata
- accession: 0001564590-22-003814
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/sndx-8k_20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-003814
- JSON: https://secwatch.observer/filing/0001564590-22-003814.json
- Plain text: https://secwatch.observer/filing/0001564590-22-003814.txt

## Key facts
- Executive change
  Briggs W. Morrison, M.D. changed role as President, Head of Research and Development at Syndax Pharmaceuticals Inc.
  - Action: transitioned
  - Role: President, Head of Research and Development
  source text: On February 2, 2022, Briggs W. Morrison, M.D., transitioned from his role as Chief Executive Officer and principal executive officer of Syndax Pharmaceuticals, Inc. (the “ Company ”) to President, Head of Research and Development of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm
- Executive change
  Michael A. Metzger was appointed as Chief Executive Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On the same date, the Board appointed Michael A. Metzger, previously the Company’s President, Chief Operating Officer, and a member of the Board, to serve as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.